Drugs / Docetaxel for Injection (Albumin-bound)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06136988 | Dec 2023 → Apr 2027 expected | esophageal squamous cell carcinoma | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Docetaxel for Injection (Albumin-bound) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06136988 ↗ |
| Route | Intravenous | “Intravenous infusion” NCT06136988 ↗ |